ATXS · As filed with the SEC
Astria Therapeutics cash flow statement, by fiscal year
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Operating activities | ||||
| Net loss | (94,260,000) | (72,891,000) | (51,834,000) | (194,912,000) |
| Reconciliation of net loss to net cash used in operating activities: | ||||
| Non-cash portion of acquired in-process research and development | — | — | — | 164,612,000 |
| Stock-based compensation expense | 13,042,000 | 6,314,000 | 4,554,000 | 3,362,000 |
| Net gain on warrants inherited in acquisition of Quellis | — | — | 1,542,000 | 71,000 |
| Right-of-use asset- operating lease | 1,004,000 | 585,000 | (554,000) | — |
| Accretion of discount/premium on investment securities | (5,611,000) | — | — | — |
| Other non-cash items | 70,000 | (40,000) | 112,000 | 21,000 |
| Changes in assets and liabilities: | ||||
| Prepaid expenses and other assets | (1,252,000) | (4,546,000) | (1,568,000) | 85,000 |
| Lease liability - operating lease | (731,000) | (610,000) | 574,000 | (109,000) |
| Accounts payable | 2,807,000 | 725,000 | (766,000) | (1,965,000) |
| Accrued expenses | 3,719,000 | 2,018,000 | 4,407,000 | (1,316,000) |
| Net cash used in operating activities | (81,212,000) | (68,445,000) | (43,533,000) | (30,151,000) |
| Investing activities | ||||
| Purchases of short-term investments | (4,244,538,000) | (1,924,423,000) | (396,064,000) | (78,000,000) |
| Sales and maturities of short-term investments | 4,053,000,000 | 2,059,500,000 | 229,026,000 | 59,000,000 |
| Cash acquired in acquisition of Quellis | — | — | — | 6,466,000 |
| Purchases of property and equipment | (325,000) | (25,000) | (91,000) | (21,000) |
| Net cash (used in) provided by investing activities | (191,863,000) | 135,052,000 | (167,129,000) | (12,555,000) |
| Financing activities | ||||
| Proceeds from public offering, net of underwriting discounts and issuance costs | 117,172,000 | 59,480,000 | 107,646,000 | — |
| Proceeds from private offering of public equity, net of issuance costs | — | — | — | 104,261,000 |
| Proceeds from at-the-market offering, net of issuance costs | 35,245,000 | 28,498,000 | 36,991,000 | — |
| Proceeds from exercise of stock options | — | — | 84,000 | 23,000 |
| Proceeds from exercise of stock options and warrants | 4,785,000 | 420,000 | — | — |
| Net cash provided by financing activities | 157,202,000 | 88,398,000 | 144,721,000 | 104,284,000 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (115,873,000) | 155,005,000 | (65,941,000) | 61,578,000 |
| Cash, cash equivalents and restricted cash, beginning of period | 175,693,000 | 20,688,000 | 86,629,000 | 25,051,000 |
| Cash, cash equivalents and restricted cash, end of period | 59,820,000 | 175,693,000 | 20,688,000 | 86,629,000 |
| Supplemental disclosure of non-cash transactions: | ||||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 5,753,000 | — | 1,268,000 | — |
| Conversion of Series X Preferred Stock into common stock | — | 1,074,000 | — | 168,920,000 |
| Non-cash dividend on convertible preferred stock | — | — | — | 24,437,000 |
| Reclassification of warrant liability to additional paid-in capital | — | — | — | 3,468,000 |
| Purchases of property and equipment in accounts payable and accrued liabilities | — | 17,000 | — | — |
| Public offering issuance costs in accrued expenses | — | 120,000 | — | — |
| Public offering issuance costs in accrued expenses | — | — | 100,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.